In addition, various markers suggestive of an active antitumor immune response within tumor tissues (for example, PD-L1 expression, tumor mutation burden and interferon (IFN)-γ production) have been reported with their associations with clinical responses to immunotherapy3–13. This evidence concerns the gene CD274 and neoplasm.